(AGENPARL) - Roma, 7 Giugno 2024 - (AGENPARL) – ven 07 giugno 2024 9.15 AM CEST / 7-Jun-2024 / Hansa Biopharma AB (STO:HNSA)
Lund, Sweden June 7, 2024. Hansa Biopharma AB, (“Hansa” or the “Company”)
(Nasdaq Stockholm: HNSA) on April 12, 2024, announced that the board of
directors had resolved on a directed share issue of 12,780,000 ordinary shares,
divided into two tranches whereby the first tranche consisted of 10,474,740
ordinary shares (the “First Tranche”) and the second tranche consisted of
2,305,260 ordinary shares (the “Second Tranche”), to a number of Swedish and
international institutional investors (the First Tranche and the Second Tranche
are jointly referred to as the “Directed Share Issue”).
A prospectus regarding admission to trading of the newly issued ordinary shares
in the Second Tranche on Nasdaq Stockholm has been approved and registered with
the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and is
available on the Company’s website (www.hansabiopharma.com) and will be
available on the SFSA’s website. Trading in the ordinary shares issued in the
Second Tranche is expected to commence on Nasdaq Stockholm on or around June 12,
2024.
The information was submitted for publication, through the agency of the contact
persons below, on June 7, 2024 at 09:15 (CEST).
— ENDS —
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
Stephanie Kenney, VP Global Corporate Affairs
Notes to editors
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a
mission to develop and commercialize innovative, lifesaving and life-altering
treatments for patients with rare immunological conditions. Hansa Biopharma has
developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme
therapy, which has been shown to enable kidney transplantation in highly
sensitized patients. Hansa Biopharma has a rich and expanding research and
development program based on the Company’s proprietary IgG-cleaving enzyme
technology platform, to address serious unmet medical needs in transplantation,
autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund,
Sweden, and has operations in Europe and the U.S. The company is listed on
Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com
and follow us on LinkedIn (https://www.linkedin.com/company/hansa-medical-ab/).
©2024 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and
IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All
rights reserved.
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/3Q1cyfAbUV9BJUB4wWzMH6awG8jiteauMXn3t23gwYvVN93xJgNDKMvFhLq3NKx896MaTrdXNPYzivoNshqspvme9XVvqfBH1sP7pDbpA5BCXV.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/3Q1cyfAbUV9BJUB4wWzMH6awG8jiteauMXn3t23gwYvVN93xJgNDKMvFhLq3NKx896MaTrdXNPYzivoNshqspvme9XVvqfBH1sP7pDbpA5BCXV.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
Trending
- Controlli sui mezzi pesanti della Polizia Locale
- Il valore della cura”, incontro alla Biblioteca Rendella
- Musei in Musica, questa sera edizione speciale di Montecitorio a porte aperte
- Disease Outbreak News: Ebola disease caused by Bundibugyo virus- Democratic Republic of the Congo, Kenya and Nigeria
- Messina, chiuso nelle ore notturne fino al 27 novembre il sottovia sulla SP 34 di Briga
- Regno Unito, la transizione energetica a emissioni zero dipende dalla Cina: allarme sulla sicurezza nazionale e sulle forniture strategiche
- MILANO, STUDENTI INNEGGIANO A MARANZA IN DUOMO, DE CORATO(FDI): «CATTIVI MAESTRI DEI CENTRI SOCIALI SONO PERICOLO PER LA CITTA’»
- Piazza San Marco si illumina: Venezia dà il via al Natale
- India, Meta oscura gli account Instagram dell’opposizione: proteste del Congresso e ultimatum di sette giorni
- PNRR e bilancio UE